The Effect of Orexin on Delayed Emergence of General Anesthesia in Dexmedetomidine

NCT ID: NCT03025295

Last Updated: 2021-06-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-01
• Study Completion Date: 2018-04-30

Brief Summary

The current study is designed to investigate the difference of plasma orexin A levels between Dexmedetomidine group and controlled group at emergence time from total intravenous anesthesia who will undergo elective lumbar surgery.

Detailed Description

DESIGNING: Fifty-one patients with ASA physical status I or II scheduled for elective surgery under general anesthesia (lasting for 2h to 4h) were enrolled. Anesthesia was induced with propofol 1-2mg/kg and sufentanyl 0.2-0.3μg/kg. Following muscle relaxation with iv cisatracurium besylate 0.2mg/kg endotracheal intubation was performed. Anesthesia was maintained with target controlled infusion propofol (targeted concentration:2-5ug/ml ) and remifentanil (targeted concentration: 2-6ng/ml ). Muscle relaxation was maintained with intermittent, but it do not injected in 1h before surgery completion. Propofol and remifentanil were titrated to maintain the bispectral index (BIS) between 40 and 60 during anesthesia. The end-tidal carbon dioxide level was maintained between 30 and 40 mmHg by controlled mechanical ventilation. When the surgery was completed the investigators adjust the targeted concentration of propofol 2ug/ml and targeted concentration of remifentanil to 2ng/ml then stop all anesthetics. Dexmedetomidine group target controlled infusion dexmedetomidine (induction dose 1ug/kg with 10min, maintain dose 0.4ug/kg/h until 30min before surgery completion). Control group infusion same saline. Record time from stopping anesthetics to emergence and total doses of anesthetics. Arterial blood (2.5ml) was collected at the following time, such as before and 1h after induction of anesthesia, at emergence (1 min after tracheal extubation) and half an hour after tracheal extubation. 2.0ml Arterial blood was centrifuged at 3000 rpm for 15min at -4 ◦C in order to separate plasma then stored at -80 ◦C until assay for orexin A concentrations. 0.5ml Arterial blood was measured blood glucose.

Conditions

Anesthesia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

Dexmedetomidine group

Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.

Group Type: EXPERIMENTAL

Dexmedetomidine

Intervention Type: DRUG

Dexmedetomidine is common used to improve the prognosis and life quality of patients.

Saline group

Control group given equal volume of saline with the dexmedetomidine group.

Group Type: PLACEBO_COMPARATOR

Saline

Intervention Type: DRUG

It is safe Placebo.

Interventions

Dexmedetomidine

Dexmedetomidine is common used to improve the prognosis and life quality of patients.

Intervention Type: DRUG

Saline

It is safe Placebo.

Intervention Type: DRUG

Other Intervention Names

Dexmedetomidine is a highly selective α2-adrenoceptor agonist.; It is safe Placebo.

Eligibility Criteria

Inclusion Criteria

1. Participant is Adult (≥18 years old and ≤60 years old)

2. Participants with a Body Mass Index (BMI) 20-25 kg/m2

3. Participants with ASA physical status Ⅰor Ⅱ

4. Participants with Heart function rating Ⅰor Ⅱ

5. Patients will undergo elective surgery and general anesthesia

6. The operation time is 2h to 4h.

Exclusion Criteria

1. Participant is a pregnant woman or a nursing mother.

2. Participants have a history of narcotics allergic reactions.

3. Indices of liver or kidney function is twice higher than normal.

4. Participants have a history or diagnosis of depression.

5. Participants have a history of Brain Trauma.

6. Participants have a history of narcotics addiction or drug addiction.

7. Participants or his family have an International Classification of Sleep

8. Disorders diagnosis of obstructive sleep apnea syndrome.

9. Patients are refuse this trail or are not able to sign informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

General Hospital of Ningxia Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zhihua Wang, M.D.

Role: STUDY_CHAIR

General Hospital of Ningxia Medical University

Locations

Anesthesiology department of General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

Countries

China

Other Identifiers

XZ2015020

Identifier Type: -

Identifier Source: org_study_id